New Funding of $10 Million Secured by Scopio Labs for Automating Blood Cell Analysis
In a groundbreaking development, Scopio Labs has launched a new AI-based Complete Blood Morphology (CBM) analyzer, set to reshape the hematology market by advancing automation and efficiency. The CBM system, which can analyze ten times more cells than current methods, has the potential to eliminate the need for routine human reviews in blood morphology analysis.
The CBM analyzer fully automates the traditionally manual, time-consuming, and subjective task of blood smear analysis by using AI algorithms and high-resolution imaging. This not only speeds up the diagnostic process but improves reproducibility and precision. With capabilities such as processing up to 40 slides per hour, systems like Scopio’s X100HT model replace manual microscopy workflows, freeing lab personnel to focus on complex cases rather than routine screens.
The high accuracy and volume of automated cell classification suggest routine human review of blood smears might become unnecessary or reserved only for flagged or exceptional cases, transforming traditional workflows and reducing human interpretation variability. This could lead to increased efficiency and throughput in hematology labs.
The CBM technology is believed to pave the way for the development of accurate and consistent morphology-based biomarkers and diagnostic panels. These biomarkers can be used for early detection and monitoring of diseases directly from blood. The goal of the CBM is to eliminate the need for routine human morphology review, potentially reshaping the entire market.
Scopio Labs aims to be the first to fully automate the hematology process from CBC to final result. The CBM is expected to deliver autonomous morphology review with depth, speed, and scalability. The automation of the hematology process could potentially reshape the entire market, accelerating the adoption of AI-enabled hematology tools and elevating diagnostic speed and patient care globally.
The drive for automation, AI integration, and point-of-care solutions in hematology is building momentum, with Scopio’s technology aligning well with market predictions of AI/ML serving as key growth drivers in diagnostic hematology through the 2020s. Viola Growth, an investor in Scopio Labs, has expressed excitement about Scopio’s journey to reshape the future of hematology diagnostics. They have invested an additional $10 million, raising Scopio’s Series D funding to $52 million.
Scopio Labs' CEO, Itai Hayut, believes the CBM will transform the hematology market, and the CBM will be showcased at the ADLM 2025 Annual Conference. The CBM technology holds CE-marked and FDA-cleared digital imaging applications, further demonstrating its potential to revolutionize hematology diagnostics.
The introduction of the CBM analyzer, an AI-driven blood morphology system developed by Scopio Labs, could revolutionize the medical-conditions sector by streamlining the identification and monitoring of diseases directly from blood samples. By leveraging science, technology, and health-and-wellness advancements, this innovation has the potential to minimize the need for human intervention in routine blood smear analysis, thereby increasing efficiency in hematology labs.
